Clorox (NYSE: CLX) reported Q3 EPS of $1.21, $0.10 better than the analyst estimate of $1.11. Revenue for the quarter came in at $1.43 billion versus the consensus estimate of $1.41 billion.

"Our 2020 strategy continues to deliver strong results," said Chief Executive Officer Benno Dorer. "Increased demand-building investments, including awareness and trial support behind product innovation, drove sales increases across all of our U.S. segments and in International on a currency-neutral basis. Importantly, we continue to drive gains in our market shares and categories."

GUIDANCE:

Clorox sees FY2016 EPS of $4.85-$4.95, versus prior guidance of $4.75-$4.90 and the consensus of $4.93. Sees 1% to 2% sales growth, or 4% to 5% currency-neutral (previously flat to 1% growth, 3% to 4% currency neutral). About 50 basis points of EBIT margin expansion (previously 50-75 basis points)

For earnings history and earnings-related data on Clorox (CLX) click here.